Provided by Tiger Trade Technology Pte. Ltd.

VanEck Healthcare TruSector ETF

29.00
+0.00010.00%
Post-market: 28.92-0.0754-0.26%16:10 EDT
Volume:1K
Turnover:33.93K
Market Cap:579.91K
PE:- -
High:29.00
Open:28.98
Low:28.92
Close:29.00
52wk High:30.68
52wk Low:24.78
Shares:20.00K
Float Shares:20.00K
Volume Ratio:1.93
T/O Rate:5.86%
Dividend:0.09
Dividend Rate:0.30%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Merck & Co Inc: Both Doses of Remigromig were Generally Well Tolerated

THOMSON REUTERS
·
Sep 24

Merck & Co - Both Remigromig Doses Show Non-Inferiority to Ranibizumab at 52 Weeks

THOMSON REUTERS
·
Sep 24

RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

TIPRANKS
·
Sep 24

RBC Capital Keeps Their Hold Rating on Merck & Company (MRK)

TIPRANKS
·
Sep 24

Johnson & Johnson (JNJ) Receives a Buy from RBC Capital

TIPRANKS
·
Sep 24

Medtronic PLC Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Sep 24

Eli Lilly & Co. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Sep 24

Johnson & Johnson Says New Analysis of Ongoing Phase 3 Trial Data Supports Potential of Multiple Myeloma Combination Therapy

MT Newswires Live
·
Sep 23

J&J Says New Model-Based Analysis Further Supports the Potential of Tecvayli Plus Darzalex Faspro

Reuters
·
Sep 23

Johnson & Johnson: Phase 3 MajesTEC-3 study shows ‘sustained’ disease control

TIPRANKS
·
Sep 23

J&J Says MajesTEC-3 Analysis Projects Near-General-Population Mortality Risk for Tecvayli-Darzalex Combo in Early Relapsed Myeloma

Reuters
·
Sep 23

J&J - Tecvayli Plus Darzalex Faspro Reduces Multiple Myeloma Progression Risk by 90% Versus Standard of Care

THOMSON REUTERS
·
Sep 23

New Model-Based Analysis Further Supports the Potential of Tecvayli® (Teclistamab-Cqyv) Plus Darzalex Faspro® (Daratumumab and Hyaluronidase-Fihj) to Redefine Long-Term Survival Expectations in Early Line Relapsed/Refractory Multiple Myeloma

THOMSON REUTERS
·
Sep 23

J&J - Analysis Estimates 87% of Tecvayli Plus Darzalex Faspro Patients Have Comparable Mortality Risk to General Population

THOMSON REUTERS
·
Sep 23

Oruka Falls After Reporting Mid-Stage Data for Psoriasis Drug

Reuters
·
Sep 23

TD Cowen Adjusts Merck Price Target to $155 From $137, Maintains Hold Rating

MT Newswires Live
·
Sep 23

Want to Bet on Risky, High-Beta Stocks? Why You Should Wait for Mid-October

Dow Jones
·
Sep 23

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Celldex (CLDX) and Inventiva (IVA)

TIPRANKS
·
Sep 23

Kimberly-Clark Offers Remedies in Bid for EU Approval of Kenvue Deal

Reuters
·
Sep 23

Novo Nordisk Open to Direct New York Listing, CEO Doustdar Tells FT

Reuters
·
Sep 23